We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




PET Detects Pancreas Defects in Newborns Very Accurately

By HospiMedica staff writers
Posted on 13 Feb 2007
The noninvasive imaging technology called positron-emission tomography (PET) has been found to be extremely accurate in diagnosing a type of congenital hyperinsulinism (HI), a rare but severe imbalance of insulin levels in newborns. More...
When the disease is confined to a limited section of the baby's pancreas, the PET scan is 100% accurate in finding the abnormal spot, and guiding surgeons to curative, organ-sparing surgery.

Investigators from the Children's Hospital of Philadelphia (PA, USA) and the University of Pennsylvania School of Medicine (Philadelphia, PA, USA) reported highly promising initial findings from a study of 24 infants referred to the Hyperinsulinism Center at the Children's Hospital between December 2004 and November 2005. All the children had congenital HI that could not be controlled with medicine. If this condition goes uncontrolled, abnormally high insulin levels may cause irreversible brain damage. The study was published in the February 2007 issue of the Journal of Pediatrics.

Congenital HI is caused by mutations that damage the insulin-secreting beta cells in the pancreas, which in an infant is smaller than an adult's little finger. When the abnormal cells are limited to a discrete portion of the pancreas, the disease is focal; when the abnormal cells are distributed throughout the organ, the disease is diffuse. Accurate diagnosis is important because focal disease can be cured by surgically removing the focal lesions. In diffuse disease, surgeons may remove nearly the entire pancreas, but that leaves the child at risk for later diabetes.

Using a mildly radioactive compound called 18F-fluoro-L-dihydroxyphenylalanine, or [18F]-DOPA, the researchers detected focal or diffuse hyperinsulinism accurately in 23 of the 24 cases, an accuracy of 96%. In the 11 cases with focal hyperinsulinism, the technique was 100% accurate in targeting the abnormal lesions. [18F]-DOPA binds to the lesions, which then are visible to the naked eye on a body scanner.

"When we compared our findings from the PET scan with pathological results, we found 100% agreement in locating the focal lesions,” said Olga T. Hardy, M.D., a pediatric endocrinologist at Children's Hospital who was the study's lead investigator. "This accuracy is superior to that of invasive, technically difficult techniques that measure insulin sampled from specific veins in an infant.”




Related Links:
Children's Hospital of Philadelphia
University of Pennsylvania School of Medicine

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.